Evofosfamide information

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Evofosfamide" – news · newspapers · books · scholar · JSTOR (March 2016) (Learn how and when to remove this message) This article needs to be updated. Please help update this article to reflect recent events or newly available information. (March 2016) A major contributor to this article appears to have a close connection with its subject. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. Please discuss further on the talk page. (December 2015) (Learn how and when to remove this message) (Learn how and when to remove this message)

Evofosfamide

Names
Preferred IUPAC name (1-Methyl-2-nitro-1H-imidazol-5-yl)methyl N,N′-bis(2-bromoethyl)phosphorodiamidate
Other names TH-302; HAP-302
Identifiers
CAS Number	918633-87-1 Y
3D model (JSmol)	Interactive image
ChEMBL	ChEMBL260046
ChemSpider	10157061 Y
KEGG	D10704 Y
PubChem CID	11984561
UNII	8A9RZ3HN8W Y
CompTox Dashboard (EPA)	DTXSID60238721
InChI InChI=1S/C9H16Br2N5O4P/c1-15-8(6-12-9(15)16(17)18)7-20-21(19,13-4-2-10)14-5-3-11/h6H,2-5,7H2,1H3,(H2,13,14,19) Y Key: UGJWRPJDTDGERK-UHFFFAOYSA-N Y
SMILES CN1C(=CN=C1[N+](=O)[O-])COP(=O)(NCCBr)NCCBr
Properties
Chemical formula	C9H16Br2N5O4P
Molar mass	449.040 g·mol−1
Solubility in water	6 to 7 g/L
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Y verify (what is YN ?) Infobox references

Evofosfamide (INN,^[1] USAN;^[2] formerly known as TH-302). Is a compound being evaluated in clinical trials for the treatment of multiple tumor types as a monotherapy and in combination with chemotherapeutic agents and other targeted cancer drugs.

This compound has been evaluated in the treatment of solid tumors, as a hypoxia-activated prodrug (HAPs), such chemical agents in low oxygen conditions undergo bio-reduction to yield cancer fighting cytotoxic breakdown products.

Many such agents have been developed, though this compound has been extensively studied, in preclinical and clinical studies.^{[3] [4]}

Dec 2015 : two Phase 3 trials fail,^{[citation needed]} Merck will not apply for a license^{[citation needed]}